Sharon Keh, O.D., F.A.A.O.
NPI 1689015372 · Optometrist · New York, NY
Enrolled with Medicare as Practitioner - Optometry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1689015372
- Entity type
- Individual
- Primary specialty
- OptometristEye and Vision Services Providers
- Credential
- O.D., F.A.A.O.
- Sex
- Female
- Sole proprietor
- Yes
- License
- TUV008046 (NY)
Specialties & taxonomies
Eye and Vision Services Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
12 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,035 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 296 | $104 |
| New Patient Office Or Other Outpatient Visit With Low Level of Medical Decision Making, If Using Time, 30 Minutes Or More99203 | 203 | $127 |
| Microfluid Analysis of Tears83861 | 96 | $22 |
| Established Patient Problem Focused Exam of Visual System92012 | 93 | $99 |
| Imaging of Retina92134 | 71 | $46 |
| Established Patient Complete Exam of Visual System92014 | 65 | $140 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 8 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Cyclosporinebrand: Restasis | 33 | 16 |
| Perfluorohexyloctane/Pfbrand: Miebo | 32 | — |
| Cyclosporine | 23 | — |
| Doxycycline Hyclate | 15 | — |
| Loteprednol Etabonate | 15 | — |
| Prednisolone Acetate | 13 | 11 |
| Lifitegrastbrand: Xiidra | 13 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$107 across 5 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2013-07-10
- Last updated
- 2026-01-28
- Certified
- 2026-01-28
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.